Roche H1 Profit Drops On Lower Revenues

Roche reported 1H net earnings attributable to shareholders of CHF 6.871B, down 7% (EPS -8% to CHF 8.52) alongside total revenue slipping 1% to CHF 31.452B. Core operating profit fell 1% to CHF 11.856B and core EPS declined 2% to CHF 10.85. While reported sales declined, constant-currency sales rose 6% (driven by demand for innovative medicines and diagnostics), partially offsetting weaker reported figures.

Analysis

The market should treat this more as an FX translation issue than a demand shock. If constant-currency sales are still advancing, the core question is whether the equity can re-rate when reported numbers keep lagging because of currency, not because the franchise is losing share. That usually caps multiple expansion in the short run, even when operating execution is intact.

Second-order, the mix matters more than the headline. If growth is being carried by innovative medicines while diagnostics remains lower-margin and procurement-sensitive, reported margin leverage can stay muted, which is why the stock can look cheaper than the underlying business really is. In relative terms, peers with cleaner reported growth or more U.S. revenue exposure—Novartis, AstraZeneca, Abbott, Danaher—may screen better over the next 1-3 months even if Roche is still competitively healthy.

The real catalyst is not the half-year print itself but whether management can keep full-year constant-currency assumptions unchanged and avoid another round of estimate cuts. If the CHF weakens or a pipeline/data readout lands, the stock can recover quickly; if the currency regime persists, the shares may remain range-bound for quarters. The contrarian read is that consensus may be overreacting to reported softness and underappreciating that underlying demand is still growing.

Key Decisions for Investors

• RHHBY: buy only on a 2%-4% post-print dip if management keeps full-year constant-currency guidance intact; target a 6%-8% rebound over 1-3 months, with a hard stop if guidance is cut or core operating profit trends down again.
• Relative value: long RHHBY / short NVS for 1-3 months if you want Swiss pharma exposure but prefer the name with better underlying sales momentum; thesis fails if Novartis re-accelerates or Roche’s FX drag widens further.
• Do not short RHHBY outright on this print; the better bearish expression is to wait for a second consecutive consensus cut or a clear deterioration in constant-currency growth, which would be the real falsifier.
• Watch item: if CHF weakens versus USD by another 3%-5% or management raises pipeline confidence, expect the 'reported weakness' narrative to unwind quickly; that would be the trigger to add rather than chase the move.